Dublin, June 09, 2023 (GLOBE NEWSWIRE) -- The "Global Breast Cancer Immunotherapy Market & Clinical Trials Forecast 2028" report has been added to ResearchAndMarkets.com's offering.
Report Highlights:
- Global Breast Cancer Immunotherapy Market Opportunity > USD 60 Billion By 2028
- Global Market and Regional Market Trends
- Global Market Forecast Till 2028
- Approved Drugs Yearly and Quarterly Sales Insight 2019 - 2023
- Approved Drugs Global and Regional Sales Insight 2019 - 2023
- Approved Drug Pricing and Dosage Analysis
- Comprehensive Insight On 250 Drugs In Clinical Trials By Company, Country, Patent
- Clinical Insight On More Than 20 Approved Biosimilars and Branded Drugs
- Competitive Landscape
With scientific progress, pharmaceutical research and development activities have led to the generation of novel and innovative therapies, which are creating a new era for cancer treatment. Immunotherapy is one such approach that has been around for years but only recently, researchers have been actively working on determining its therapeutic potential. Continuous innovation in breast cancer treatment has enabled the breakthrough of several novel immunotherapeutic approaches.
While conventional methods like surgery and chemotherapy have become primary therapeutic options, their long-lasting side effects and the growing possibility of developing drug resistance and cancer recurrence have called for the development of more effective treatment options. The introduction of immunotherapy, particularly immune checkpoint inhibitors has transformed the treatment for breast cancer, with immunotherapy being effective even in aggressive forms of breast cancer such as triple-negative breast cancer.
The growing demand for therapies having minimal adverse effects, improved drug development, increasing cancer incidence, and growing adoption of cancer immunotherapy above other available treatment options are key factors that are propelling the growth of the market. Moreover, approved immunotherapeutic drugs for breast cancer showing robust sales has been another factor that has resulted in a growing number of investments in the market.
Keytruda, developed by Merck has been a "blockbuster" immune checkpoint inhibitor approved for breast cancer. Since, its approval, the immunotherapy drug has only witnessed exponential growth in its annual sales. Moreover, Merck has also played strategically by introducing several combinations of this blockbuster immunotherapy drug with other treatments, creating a wider range of patient populations choosing Keytruda over other methods.
It can be said that immune checkpoint inhibitors have been a vital factor that has resulted in the growing market of breast cancer immunotherapy. Following Keytruda, several companies have launched their respective immune checkpoint blockers; however, none has had higher success than Keytruda. The improved understanding of immune evasion by cancer cells and the development of antibodies towards tumor-associated antigens have led to the enhanced growth observed in immunotherapy for breast cancer.
Additionally, moving beyond immune checkpoint inhibitors, the market of breast cancer immunotherapy is also witnessing a rise in novel treatment approaches. For instance, several pharmaceutical companies have been transforming different novel immunotherapy options for breast cancer treatment, like bispecific antibodies, oncolytic viruses, cancer vaccines, tumor-infiltrating lymphocyte therapy, and cell and gene therapies. While some of these methods have had a huge impact on hematological malignancies, pharmaceutical companies are not investigating their potential therapeutic application for breast treatment.
For the last two decades, monoclonal antibody-based therapies have brought in incredible changes in the field of breast cancer treatment, however, over time with the surge of bispecific antibodies, several clinical trials are evaluating their therapeutic potential in breast cancer. The possibility of engaging the immune system while simultaneously targeting tumor-specific antigens is expected to generate a more robust immune response. In the future, it is easily predictable that bispecific antibodies will change the treatment landscape for breast cancer immunotherapy.
Another immunotherapeutic approach that is currently gardening significant attention for researchers all over the world is tumor-infiltrating lymphocyte (TIL) therapy. Studies have shown that TILs are one of the strongest biomarkers present specifically for triple-negative breast cancer patients and could also possibly be factors resulting in a positive prognosis of the disease. Hence, as we move towards immunotherapy for breast cancer, the evaluation of tumor-infiltrating lymphocytes could be a very affordable and valuable approach that can be combined with already existing or newly emerging techniques.
Additionally, the involvement of academic institutions and research centers has also played a significant role in transforming the global market of breast cancer immunotherapy. Collaborating between pharmaceutical companies as well as academic instructions has been driving innovation in the field, creating a robust portfolio of immunotherapy candidates in the market. With increasing breast cancer incidence, there also grows a significant need to develop more effective therapeutic approaches and the onset of immunotherapy has offered a promising future.
The report provides an in-depth analysis of the commercially available breast cancer immunotherapy drugs. The report describes the current market of breast cancer immunotherapy with insights into the market growth while also highlighting the impact on regional sales, pricing, dosage, and patent expiration dates. Moreover, the report also includes new trends in the breast cancer immunotherapy market, information about company collaborations, and partnerships.
Key Topics Covered:
1. Need For Breast Cancer Immunotherapy
1.1 Overview
1.2 Breast Cancer Immunotherapy Mechanism Of Action
1.3 Potential Breast Cancer Biomarkers
2. Global Breast Cancer Immunotherapy Market Overview
2.1 Breast Cancer Global Market Insight: Yearly and Quarterly Sales (2019 - 2023)
2.2 Global Breast Cancer Immunotherapy Market Future Outlook (2023 - 2028)
3. Global Breast Cancer Immunotherapy Trend Analysis
3.1 US
3.2 UK
3.3 Canada
3.4 Europe
3.4.1 Germany
3.4.2 France
3.4.3 Italy
3.4.4 Spain
3.4.5 Poland
3.4.6 Belgium
3.5 Australia
3.6 China
3.7 Japan
3.8 South Korea
3.9 India
4. Global Breast Cancer Immunotherapy Approved Drugs Sales, Price, Dosage and Patent Analysis
4.1 Keytruda (Pembrolizumab)
4.2 Perjeta (Pertuzumab)
4.3 Kadcyla (Ado-Trastuzumab Emtansine)
4.4 Phesgo (pertuzumab trastuzumab hyaluronidase)
4.5 Trodelvy (Sacituzumab Govitecan)
4.6 Herceptin (Trastuzumab)
4.7 Enhertu (Fam-Trastuzumab Deruxtecan)
4.8 Margenza (Margetuximab)
4.9 Tecentriq (Atezolizumab)
4.10 Avastin (Bevacizumab)
5. Global Breast Cancer Immunotherapies Clinical Trials Insight
5.1 By Biomarker
5.2 By Company
5.3 By Country
5.4 By Patient Segment
5.5 By Phase
6. Global Breast Cancer Immunotherapies Clinical Trials By Company, Country and Indication
6.1 Research
6.2 Preclinical
6.3 Phase-I
6.4 Phase-I/II
6.5 Phase-II
6.6 Phase-II/III
6.7 Phase-III
6.8 Preregistration
6.9 Registered
7. Marketed Breast Cancer Immunotherapies Clinical Insight
8. Therapeutic Approaches To Breast Cancer Immunotherapy
8.1 Monotherapeutic Approaches
8.2 Combination Therapy Approach
8.2.1 Combination Of Targeted Therapy and Endocrine Therapy
8.2.2 Combination With Immunotherapy
8.2.3 Combination Strategies That Include Triple Agents
9. New Immunotherapeutic Approaches In Trials For Breast Cancer Treatment
9.1 Emerging Molecular Targets For CAR T Cell Immunotherapy
9.2 Bispecific Antibodies
9.3 Vaccine Based Therapy
9.4 Oncolytic Viruses
9.5 Immunotherapy with Tumor Infiltrating Lymphocytes (TILs)
9.6 Cytokine Therapy
10. Global Breast Cancer Immunotherapy Market Dynamics
10.1 Market Drivers
10.2 Market Challenges
11. Competitive Landscape
11.1 Roche
11.2 Genentech
11.3 Amgen
11.4 Antibody Therapeutics
11.5 Pfizer
11.6 Merck
11.7 Novartis
11.8 Bristol-Myers Squibb
11.9 EirGenix
11.10 Prestige BioPharma
11.11 Novartis Oncology
11.12 Protheragen
11.13 Merck
11.14 LeadArtis
11.15 Mayo Clinic
11.16 Biocad
11.17 Therabest Korea
11.18 EpiThany
11.19 AstraZeneca
11.20 PACT Pharma
11.21 Xuanzhu Biopharmaceutical
11.22 Samsung Bioepis
11.23 Shanghai Novamab Biopharmaceuticals
11.24 ImmunityBio
For more information about this report visit https://www.researchandmarkets.com/r/fu4krb
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
